Bio-Thera Solutions

Bio-Thera Solutions Equity

The The Equity of Bio-Thera Solutions (688177.SS) as of Nov 5, 2026 is 376.03 M CNY. In the previous year, The Equity was 708.09 M CNY — a change of -46.89% (lower).

Equity

376.03 MCNY

YoY

-46.89%

Last updated:

In 2025, Bio-Thera Solutions's equity was 376.03 M CNY, a -46.89% increase from the 708.09 M CNY equity in the previous year.

The Bio-Thera Solutions Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
801.32 M CNY
Jan 1, 2019
630.67 M CNY
Jan 1, 2020
2.01 B CNY
Jan 1, 2021
2.09 B CNY
Jan 1, 2022
1.61 B CNY
Jan 1, 2023
1.21 B CNY
Jan 1, 2024
708.09 M CNY
Jan 1, 2025
376.03 M CNY
The Bio-Thera Solutions Equity history
YEAREquityYoY
376.03 MCNY-46.89%
708.09 MCNY-41.61%
1.21 BCNY-24.55%
1.61 BCNY-23.01%
2.09 BCNY+4.08%
2.01 BCNY+218.01%
630.67 MCNY-21.30%
801.32 MCNY+130.56%
347.55 MCNY-34.97%
534.43 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio-Thera Solutions Stock analysis

What does Bio-Thera Solutions do? Bio-Thera Solutions Ltd. generates revenue through the research, development, and production of innovative drugs and biosimilar drugs targeting tumours, autoimmune diseases, cardiovascular diseases, and other major health conditions. The company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, and BAT8003, which are developed for treating cancer, autoimmune diseases, cardiovascular diseases, and other life-threatening illnesses. These products are sold to healthcare providers and pharmaceutical distributors in markets where the company operates. The primary customer segments consist of hospitals, clinics, and healthcare institutions seeking advanced therapeutic solutions for chronic and serious diseases. The firm focuses on developing antibody drugs as part of its commitment to addressing major health threats. Its product portfolio targets high-demand therapeutic areas such as oncology, immunology, and cardiology, aligning with global healthcare needs. By offering biosimilar alternatives to established biologics, Bio-Thera Solutions Ltd. provides cost-effective treatment options while maintaining clinical efficacy. This strategy attracts healthcare systems and institutions looking to reduce treatment costs without compromising patient outcomes. The company's revenue streams are derived from the commercialization of its drug pipeline, including both innovative and biosimilar products. Its main products are designed to treat conditions like cancer, autoimmune disorders, and cardiovascular diseases, which represent significant market segments. Healthcare providers and pharmaceutical distributors purchase these drugs for use in patient care, supporting the company's growth in the pharmaceutical sector. Bio-Thera Solutions is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bio-Thera Solutions's Equity

Bio-Thera Solutions's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bio-Thera Solutions's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bio-Thera Solutions's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bio-Thera Solutions's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bio-Thera Solutions’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bio-Thera Solutions stock

The Equity of Bio-Thera Solutions is 376.03 M CNY in 2025.

The Equity of Bio-Thera Solutions changed from 708.09 M CNY to 376.03 M CNY, representing a -46.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bio-Thera Solutions since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bio-Thera Solutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Bio-Thera Solutions

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Bio-Thera Solutions